 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || TRV045 / Trevena
$TRVN Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial Evaluating S1PR Mechanism of Action and Target Engagement https://t.co/WbdswE86nw (Twitter) - Jan 9, 2023
- TRV045 / Trevena
TRV045, a Novel, Selective S1P Receptor subtype-1 Modulator that Does Not Cause lymphopenia, Is Efficacious in Acute and Chronic Rodent Epilepsy Models (Grand Saguaro) - Oct 31, 2022 - Abstract #ACNP2022ACNP_912;
Fingolimod, a nonselective S1PR modulator but with high potency for S1PR1, has shown anti-epileptic effects in a diverse range of preclinical epileptic models, possibly through anti-inflammatory mechanisms as well as preservation of neuronal and blood brain barrier integrity. The S1PR1 modulator TRV045 prevented generalized seizures in the CK mouse and rat MES models and reduced seizures in the KA-SRS chronic spontaneous seizure model, indicating that it is a viable candidate for human research in the treatment of epilepsy.
- TRV045 / Trevena
[VIRTUAL] TRV045, a Novel, Selective S1P1 Receptor Modulator is Efficacious in Rodent Models of Epilepsy, Without Affecting Lymphocyte Trafficking () - Sep 30, 2020 - Abstract #ACNP2020ACNP_585;
We have shown that the S1P1R¬selective compound TRV045 prevented generalized seizures in a rat MES model and demonstrated anti-convulsant activity in a corneal kindled mouse model. These data suggest that the novel mechanism of action of TRV045 may provide a new therapeutic option for the treatment of epilepsy.
- TRV045 / Trevena
[VIRTUAL] TRV045, a Novel, Selective S1P1 Receptor Modulator, is Efficacious in Reversing Neuropathic Pain Without Affecting Lymphocyte Trafficking () - Sep 30, 2020 - Abstract #ACNP2020ACNP_381;
TRV045 differentiates from other non-selective S1P receptor modulators in that it does not cause lymphopenia. Therefore, TRV045 may provide a new therapeutic option for the treatment of neuropathic pain.